Published in J Antimicrob Chemother on July 12, 2006
Protein binding: do we ever learn? Antimicrob Agents Chemother (2011) 1.46
Effect of protein binding on the pharmacological activity of highly bound antibiotics. Antimicrob Agents Chemother (2008) 1.16
Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents. Clin Microbiol Rev (2013) 0.99
Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients. Antimicrob Agents Chemother (2009) 0.88
Protein binding of antimicrobials: methods for quantification and for investigation of its impact on bacterial killing. AAPS J (2009) 0.85
The treatment of diabetic foot infections: focus on ertapenem. Vasc Health Risk Manag (2009) 0.82
Penetration of ertapenem into muscle measured by in vivo microdialysis in mechanically ventilated patients. Antimicrob Agents Chemother (2011) 0.77
Population Pharmacokinetics and Target Attainment of Ertapenem in Plasma and Tissue Assessed via Microdialysis in Morbidly Obese Patients after Laparoscopic Visceral Surgery. Antimicrob Agents Chemother (2016) 0.75
Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing. Clin Ther (2016) 0.75
In silico fragmentation for computer assisted identification of metabolite mass spectra. BMC Bioinformatics (2010) 2.61
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother (2005) 2.50
Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet (2006) 2.32
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob Agents Chemother (2004) 2.10
Tissue concentrations: do we ever learn? J Antimicrob Chemother (2007) 1.92
Are we regionalized enough? Early-neonatal deaths in low-risk births by the size of delivery units in Hesse, Germany 1990-1999. Int J Epidemiol (2002) 1.82
Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci U S A (2004) 1.80
In vitro and in vivo evaluation of [18F]ciprofloxacin for the imaging of bacterial infections with PET. Eur J Nucl Med Mol Imaging (2004) 1.67
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother (2004) 1.64
Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil. Epilepsia (2007) 1.55
Protein binding: do we ever learn? Antimicrob Agents Chemother (2011) 1.46
Improved in vivo detection of cortical lesions in multiple sclerosis using double inversion recovery MR imaging at 3 Tesla. Eur Radiol (2010) 1.41
PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother (2010) 1.38
Significance of protein binding in pharmacokinetics and pharmacodynamics. J Pharm Sci (2010) 1.37
How important are gender differences in pharmacokinetics? Clin Pharmacokinet (2002) 1.37
AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res (2007) 1.35
Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments. Antimicrob Agents Chemother (2006) 1.34
Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies. J Lipid Res (2009) 1.29
Impact of the 3D microenvironment on phenotype, gene expression, and EGFR inhibition of colorectal cancer cell lines. PLoS One (2013) 1.27
Absorption, metabolism, and antioxidant effects of pomegranate (Punica granatum l.) polyphenols after ingestion of a standardized extract in healthy human volunteers. J Agric Food Chem (2006) 1.26
Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet (2010) 1.25
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int J Antimicrob Agents (2002) 1.24
Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int J Antimicrob Agents (2002) 1.23
Duffy antigen modifies the chemokine response in human endotoxemia. Crit Care Med (2008) 1.20
Effect of protein binding on the pharmacological activity of highly bound antibiotics. Antimicrob Agents Chemother (2008) 1.16
Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents. Expert Rev Anti Infect Ther (2005) 1.14
Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains. Int J Antimicrob Agents (2006) 1.13
Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development? J Antimicrob Chemother (2006) 1.12
Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models. Int J Antimicrob Agents (2005) 1.11
Tobacco smoke exposure induces nicotine dependence in rats. Psychopharmacology (Berl) (2009) 1.11
Dysregulated autophagy in the RPE is associated with increased susceptibility to oxidative stress and AMD. Autophagy (2014) 1.11
Hyperforin in St. John's wort drug interactions. Eur J Clin Pharmacol (2006) 1.10
Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J Antimicrob Chemother (2006) 1.09
Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am (2005) 1.07
Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol (2004) 1.07
Pharmacokinetic/pharmacodynamic studies in drug product development. J Pharm Sci (2002) 1.06
Population kinetics, efficacy, and safety of dichloroacetate for lactic acidosis due to severe malaria in children. J Clin Pharmacol (2003) 1.05
Pharmacokinetics and bioavailability of herbal medicinal products. Phytomedicine (2002) 1.04
Does high field MRI allow an earlier diagnosis of multiple sclerosis? J Neurol (2008) 1.04
Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers. Int J Antimicrob Agents (2012) 1.03
Long-term engraftment of bone marrow-derived cells in the intimal hyperplasia lesion of autologous vein grafts. Am J Pathol (2008) 1.03
Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/pharmacodynamic indices. Int J Antimicrob Agents (2010) 1.03
Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol (2003) 1.02
Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. Int J Antimicrob Agents (2005) 1.02
Pharmacokinetics of anthocyanins and antioxidant effects after the consumption of anthocyanin-rich acai juice and pulp (Euterpe oleracea Mart.) in human healthy volunteers. J Agric Food Chem (2008) 1.01
Soft tissue penetration of cefuroxime determined by clinical microdialysis in morbidly obese patients undergoing abdominal surgery. Int J Antimicrob Agents (2009) 1.01
AAPS-FDA Workshop White Paper: microdialysis principles, application, and regulatory perspectives. J Clin Pharmacol (2007) 1.01
Profiling of secondary metabolites in root exudates of Arabidopsis thaliana. Phytochemistry (2014) 0.99
Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents. Clin Microbiol Rev (2013) 0.99
PK/PD: new insights for antibacterial and antiviral applications. Curr Opin Pharmacol (2008) 0.98
Population pharmacokinetic model of human insulin following different routes of administration. J Clin Pharmacol (2010) 0.98
In vitro pharmacodynamic models to determine the effect of antibacterial drugs. J Antimicrob Chemother (2009) 0.98
Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice. Expert Opin Pharmacother (2007) 0.98
Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma. Br J Clin Pharmacol (2006) 0.98
Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol (2013) 0.98
Role of pharmacokinetics in establishing bioequivalence for orally inhaled drug products: workshop summary report. J Aerosol Med Pulm Drug Deliv (2011) 0.97
Simulation-based sodium thiosulfate dosing strategies for the treatment of calciphylaxis. Clin J Am Soc Nephrol (2011) 0.97
Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. J Antimicrob Chemother (2013) 0.96
Clinical pharmacokinetics and pharmacodynamics of tigecycline. Clin Pharmacokinet (2009) 0.96
Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol (2004) 0.96
Clinical microdialysis in skin and soft tissues: an update. J Clin Pharmacol (2008) 0.96
Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily. Br J Clin Pharmacol (2011) 0.94
Pharmacometrics as a discipline is entering the "industrialization" phase: standards, automation, knowledge sharing, and training are critical for future success. J Clin Pharmacol (2010) 0.94
Interstitial tissue concentrations of cefpodoxime. J Antimicrob Chemother (2002) 0.93
How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thorac Soc (2004) 0.93
Feasibility of a breath test for monitoring adherence to vaginal administration of antiretroviral microbicide gels. J Clin Pharmacol (2013) 0.93
The Candida albicans phosphatase Inp51p interacts with the EH domain protein Irs4p, regulates phosphatidylinositol-4,5-bisphosphate levels and influences hyphal formation, the cell integrity pathway and virulence. Microbiology (2008) 0.93
Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. Eur J Med Res (2010) 0.93
A sensitive liquid chromatography-tandem mass spectrometry method for the quantification of mometasone furoate in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 0.93
Variation of flavonoids and furanocoumarins in grapefruit juices: a potential source of variability in grapefruit juice-drug interaction studies. J Agric Food Chem (2006) 0.93
Soluble Flt-1 gene therapy ameliorates albuminuria but accelerates tubulointerstitial injury in diabetic mice. Am J Physiol Renal Physiol (2009) 0.92
A pharmacokinetic/pharmacodynamic mathematical model accurately describes the activity of voriconazole against Candida spp. in vitro. Int J Antimicrob Agents (2008) 0.92
Evaluation of quantitative ultrasound tissue characterization of the cervix and cervical length in the prediction of premature delivery for patients with spontaneous preterm labor. Am J Obstet Gynecol (2003) 0.91
Grapefruit-medication interactions. CMAJ (2013) 0.91
Single- and multiple-dose pharmacokinetics of oral creatine. J Clin Pharmacol (2003) 0.91
Antimicrobial tissue concentrations. Infect Dis Clin North Am (2003) 0.91
Physiological, pharmacokinetic, and pharmacodynamic changes in space. J Clin Pharmacol (2004) 0.91
Combined PET and microdialysis for in vivo assessment of intracellular drug pharmacokinetics in humans. J Nucl Med (2005) 0.90
Discriminatory features of acute transverse myelitis: a retrospective analysis of 45 patients. J Neurol Sci (2004) 0.90
Underdosing of ertapenem in critically ill patients with pneumonia confirmed by Monte Carlo simulations. Int J Antimicrob Agents (2009) 0.89
Microdialysis for in vivo pharmacokinetic/pharmacodynamic characterization of anti-infective drugs. Curr Opin Pharmacol (2005) 0.88
Carbohydrate-lectin recognition of sequence-defined heteromultivalent glycooligomers. J Am Chem Soc (2014) 0.88
Computer-assisted detection of pulmonary embolism: performance evaluation in consensus with experienced and inexperienced chest radiologists. Eur Radiol (2007) 0.88
Measurement of voriconazole activity against Candida albicans, C. glabrata, and C. parapsilosis isolates using time-kill methods validated by high-performance liquid chromatography. Antimicrob Agents Chemother (2007) 0.88
Systemic availability and pharmacokinetics of thymol in humans. J Clin Pharmacol (2002) 0.87
Synthesis of fluorine-18-labeled ciprofloxacin for PET studies in humans. Nucl Med Biol (2003) 0.87
Anti-S-nitrosocysteine antibodies are a predictive marker for demyelination in experimental autoimmune encephalomyelitis: implications for multiple sclerosis. J Neurosci (2002) 0.87
Plasma concentrations of fluticasone propionate and budesonide following inhalation: effect of induced bronchoconstriction. Br J Clin Pharmacol (2007) 0.87
SDF1-alpha is associated with VEGFR-2 in human choroidal neovascularisation. Microvasc Res (2007) 0.87